MPhil Cancer

Newcastle University

MPhil Cancer

  • Country United Kingdom
  • Course Duration 12 month
  • Course Type Full Time
  • Courses Campus On Campus
  • Language Specification IELTS
  • Program Level Post-Graduate
  • Education Required Graduate
  • Admission intake SEP
  • Minimum GPA 3.3
Login & Apply

Application Charges

Application Fee Tution Fee
Free GBP 26,100

Application Date

Application Start Date Application Closing Date
2022-12-07
2023-01-10

Program Description

Our staff and postgraduate students work in the Faculty of Medical Sciences or in the School of Natural and Environmental Sciences. The NICR incorporates the Newcastle Cancer Centre. This is a unique collaboration between Cancer Research UK and the North of England Children's Cancer Research Fund.Work covers a broad spectrum:
  • understanding the biological differences between normal and malignant cells
  • understanding the molecular differences between normal and malignant cells
  • using this knowledge to develop new anti-cancer drugs
We're a major training base for the next generation of cancer researchers. Our Institute covers many areas of cancer research, including:
  • solid tumours and leukaemias
  • childhood and adult cancers
  • drug discovery and early phase clinical trials
Exploratory biology, target and biomarker discovery
Molecular genetic and mechanistic studies identify critical molecular changes in cancer. It identifies the relevance to disease development and progression. We use these biomarkers and targets for therapeutic intervention. We use a wide range of techniques, including:
  • contemporary genomic
  • bioinformatic
  • molecular biology
  • biochemical
  • cell biology
Studies focus on:
  • haematological malignancies (leukaemia and lymphoma)
  • paediatric solid tumours (neuroblastoma and medulloblastoma),
  • adult solid tumours (eg breast, ovarian, prostate, bladder and liver cancers).
Biomarker development
We exploit critical molecular defects as biomarkers to enhance:
  • disease detection and diagnosis
  • prediction of disease course
  • sensitivity to specific drugs
  • therapeutic monitoring.
We play leading roles in molecular diagnostics, biomarker assessment and therapeutic monitoring. This is for national and international clinical trials.
Drug development
The use of rational drug design helps achieve the exploitation of novel targets. It is through the use of structure-based design, in conjunction with medium-throughout screening. Target molecule synthesis and varied parallel synthesis approaches result in lead optimisation. Candidate drugs undergo evaluation in cell-free and whole-cell target-based assays.
Clinical trials
Clinical trials (Phase I/II/III) are undertaken in both adults and children. Trials have a strong hypothesis-testing translational research component. They are performed under:
  • national or international research networks (eg CR–UK, Children's Cancer
  • Leukaemia Group, European Organisation for Research and Treatment of Cancer)
  • in collaboration with the pharmaceutical industry
We are one of the few academic centres in the UK able to undertake this specialist cancer research. We achieve this through:
  • our expert staff
  • state of the art facilities
  • close working relationships with the pharmaceutical and biotechnology sectors
  • clinical trials networks
We offer approximately 15 MD, PhD and integrated MRes/PhD studentships each year. This includes the Newcastle Cancer Centre training programme. Projects in all research areas are available to fully-funded international students.Members of our postgraduate community come from a variety of subject backgrounds. This includes:
  • biological and biomedical sciences
  • chemistry
  • genetics
  • pharmacy
  • medicine
  • dentistry
  • veterinary medicine